Osteoarthritis : the inflammatory reaction and medical treatment
Osteoarthritis is a common and important problem in performance horses and symptoms include lameness accompanied with heat, pain and joint swelling. Several different diagnostic methods exist. However, detection of early stages of inflammation is problematic; hence assays for biochemical markers,...
| Autor principal: | |
|---|---|
| Formato: | L3 |
| Lenguaje: | Inglés sueco |
| Publicado: |
SLU/Dept. of Biomedical Sciences and Veterinary Public Health (until 231231)
2007
|
| Materias: |
| _version_ | 1855571851313414144 |
|---|---|
| author | Andersson, Anna-Maria |
| author_browse | Andersson, Anna-Maria |
| author_facet | Andersson, Anna-Maria |
| author_sort | Andersson, Anna-Maria |
| collection | Epsilon Archive for Student Projects |
| description | Osteoarthritis is a common and important problem in performance horses and
symptoms include lameness accompanied with heat, pain and joint swelling.
Several different diagnostic methods exist. However, detection of early stages of
inflammation is problematic; hence assays for biochemical markers, such as the
cytokines, are considered a possible way to monitor inflammation. Many of the
cytokines are mediators released in the process of inflammation and one important
example is tumor necrosis factor alpha (TNFα).
In this pilot study of five horses, an ELISA was used to measure TNFα in synovial
fluid from fetlock joints. This was performed in order to evaluate if any
inflammatory reaction against intra-articularly injected hyaluronan X (hyaluronic
acid) was present. Hyaluronan X is a new product with a higher molecular weight
compared to hyaluronic suspensions commonly used in equine practice for the
treatment of osteoarthritis.
All the horses showed clinical signs of joint inflammation at some point.
However, only one of the five horses presented a detectable level of TNFα in
synovial fluid from the fetlock joint. Unfortunately, the hyaluronan X had been
contaminated with ethanol during the manufacture and hence no conclusions
about the side effects of this new hyaluronic suspension could be drawn. In future
studies, a revised study design with repeated sampling of synovial fluid from
experimental joints as well as control joints must be developed. In addition, the
manufacturing of the hyaluronic suspension must be improved. |
| format | L3 |
| id | RepoSLU11326 |
| institution | Swedish University of Agricultural Sciences |
| language | Inglés swe |
| publishDate | 2007 |
| publishDateSort | 2007 |
| publisher | SLU/Dept. of Biomedical Sciences and Veterinary Public Health (until 231231) |
| publisherStr | SLU/Dept. of Biomedical Sciences and Veterinary Public Health (until 231231) |
| record_format | eprints |
| spelling | RepoSLU113262017-10-10T07:28:04Z Osteoarthritis : the inflammatory reaction and medical treatment Osteoartrit : den inflammatoriska reaktionen och medicinsk behandling Andersson, Anna-Maria osteoarthritis degenerative joint disease DJD traumatic arthritis equine arthritis equine osteoarthritis joint structure joint function articular cartilage cartilage degeneration cartilage degradation TNFa tumour necrosis factor tumor necrosis factor markers of joint disease inflammatory mediators mediators of inflammation cytokine joint treatment medical treatment of joint disease treatment of equine joint disease hyaluronic acid hyaluronan Osteoarthritis is a common and important problem in performance horses and symptoms include lameness accompanied with heat, pain and joint swelling. Several different diagnostic methods exist. However, detection of early stages of inflammation is problematic; hence assays for biochemical markers, such as the cytokines, are considered a possible way to monitor inflammation. Many of the cytokines are mediators released in the process of inflammation and one important example is tumor necrosis factor alpha (TNFα). In this pilot study of five horses, an ELISA was used to measure TNFα in synovial fluid from fetlock joints. This was performed in order to evaluate if any inflammatory reaction against intra-articularly injected hyaluronan X (hyaluronic acid) was present. Hyaluronan X is a new product with a higher molecular weight compared to hyaluronic suspensions commonly used in equine practice for the treatment of osteoarthritis. All the horses showed clinical signs of joint inflammation at some point. However, only one of the five horses presented a detectable level of TNFα in synovial fluid from the fetlock joint. Unfortunately, the hyaluronan X had been contaminated with ethanol during the manufacture and hence no conclusions about the side effects of this new hyaluronic suspension could be drawn. In future studies, a revised study design with repeated sampling of synovial fluid from experimental joints as well as control joints must be developed. In addition, the manufacturing of the hyaluronic suspension must be improved. Ledinflammation (osteoartrit) är ett viktigt problem hos arbetande hästar och manifesteras som hälta med associerad värme, smärta och ledsvullnad. Flera olika diagnostiska metoder finns att tillgå men tidiga stadier av inflammation är svåra att upptäcka. Därför analyseras olika biokemiska och inflammatoriska markörer i både ledvätska och serum. Dessa markörer inkluderar de olika mediatorer som frisätts i samband med den inflammatoriska processen i leden och ett viktigt exempel är inflammationscytokinen tumör-nekros-faktor alfa (TNFα). I den nedan beskrivna pilotstudien med fem hästar injicerades kotleden i ett framben med hyaluronsyra X och den kontralaterala leden användes som kontroll. Hyaluronsyra X är en ny produkt med högre molekylvikt än de som idag används vid behandling av osteoartrit hos häst. En hästspecifik ELISA användes sedan för mätning av TNFα i ledvätska. Tanken med detta var att utvärdera huruvida injektionen av hyaluronsyra X gav upphov till en inflammatorisk reaktion i leden. Alla fem hästarna i studien visade kliniska tecken på ledinflammation men bara en av dem hade ett förhöjt värde av TNFα i kotleden. Tyvärr var hyaluronsyrasuspensionen vid ett par tillfällen kontaminerad av etanol vilket i sig kan leda till inflammation i leden. Därför kan inga slutsatser om eventuella biverkningar av preparatet dras från denna studie. Inför uppföljande studier bör tillverkningen av hyaluronsyra X förbättras och kvalitetssäkras. Dessutom måste studiedesignen förändras så att upprepade ledvätskeprover tas från både försöksleden och kontrolleden vid samma tillfällen. SLU/Dept. of Biomedical Sciences and Veterinary Public Health (until 231231) 2007 L3 eng swe https://stud.epsilon.slu.se/11326/ |
| spellingShingle | osteoarthritis degenerative joint disease DJD traumatic arthritis equine arthritis equine osteoarthritis joint structure joint function articular cartilage cartilage degeneration cartilage degradation TNFa tumour necrosis factor tumor necrosis factor markers of joint disease inflammatory mediators mediators of inflammation cytokine joint treatment medical treatment of joint disease treatment of equine joint disease hyaluronic acid hyaluronan Andersson, Anna-Maria Osteoarthritis : the inflammatory reaction and medical treatment |
| title | Osteoarthritis : the inflammatory reaction and medical treatment |
| title_full | Osteoarthritis : the inflammatory reaction and medical treatment |
| title_fullStr | Osteoarthritis : the inflammatory reaction and medical treatment |
| title_full_unstemmed | Osteoarthritis : the inflammatory reaction and medical treatment |
| title_short | Osteoarthritis : the inflammatory reaction and medical treatment |
| title_sort | osteoarthritis : the inflammatory reaction and medical treatment |
| topic | osteoarthritis degenerative joint disease DJD traumatic arthritis equine arthritis equine osteoarthritis joint structure joint function articular cartilage cartilage degeneration cartilage degradation TNFa tumour necrosis factor tumor necrosis factor markers of joint disease inflammatory mediators mediators of inflammation cytokine joint treatment medical treatment of joint disease treatment of equine joint disease hyaluronic acid hyaluronan |